The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study.
dysbiosis
fibrosis
gut microbiota
liver steatosis
small intestinal bacterial overgrowth
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
02
2022
accepted:
18
03
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Gut microbiota are a complex ecosystem harboring our intestine. They maintain human body equilibrium, while their derangement, namely, "dysbiosis", has been associated with several gastrointestinal diseases, such as liver steatosis (NAFLD) and liver cirrhosis. Small intestinal bacterial overgrowth (SIBO) is an example of dysbiosis of the upper gastrointestinal (GI) tract. The aim of this study is to evaluate the relationship between SIBO and levels of endotoxemia and grade of liver steatosis (LS) and liver fibrosis (LF) in hepatologic patients. Consecutive outpatients referred to our hepatology clinic were tested for SIBO by the lactulose breath test (LBT) and peripheral blood levels of endotoxemia; LS grading and LF were assessed by abdominal ultrasound and transient elastography, respectively. Fifty-two consecutive patients (17 with alcohol abuse (4.5 ± 0.8 alcohol units per day), 4 with HCV and 2 with HBV infection, 24 of metabolic origin, 2 of autoimmune origin, and 3 with cholangiopathies; mean age 54.7 ± 8.3 years, 31 F, BMI 24.1 ± 1.1 Kg/m This study shows that SIBO prevalence and relative endotoxin blood levels seem to be significantly associated with the grade of LF vs. LS in LC. SIBO is also present under pre-cirrhotic conditions, but its prevalence seems to correlate with liver disease irreversible derangement.
Identifiants
pubmed: 35559337
doi: 10.3389/fmed.2022.872428
pmc: PMC9090439
doi:
Types de publication
Journal Article
Langues
eng
Pagination
872428Informations de copyright
Copyright © 2022 Scarpellini, Abenavoli, Cassano, Rinninella, Sorge, Capretti, Rasetti, Svegliati Baroni, Luzza, Santori and Sciacqua.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2021 Feb 3;16(2):e0245762
pubmed: 33534815
Liver Int. 2008 Aug;28(7):1026-33
pubmed: 18397235
Sci Rep. 2016 Aug 23;6:32002
pubmed: 27550547
Arq Gastroenterol. 2020 Oct-Dec;57(4):471-476
pubmed: 33331479
Aliment Pharmacol Ther. 2009 Mar 30;29 Suppl 1:1-49
pubmed: 19344474
Aliment Pharmacol Ther. 2007 Apr 1;25(7):781-6
pubmed: 17373916
Eur J Gastroenterol Hepatol. 2020 May;32(5):601-608
pubmed: 31567712
Hepatology. 2009 Jun;49(6):1877-87
pubmed: 19291785
J Gastroenterol Hepatol. 2016 Jan;31(1):213-21
pubmed: 26212089
Lancet. 2021 Jun 5;397(10290):2212-2224
pubmed: 33894145
FASEB J. 2019 Oct;33(10):11595-11605
pubmed: 31345057
Panminerva Med. 2021 Dec;63(4):508-518
pubmed: 33165307
J Hepatol. 2011 Apr;54(4):650-9
pubmed: 21146892
Minerva Med. 2020 Dec;111(6):526-528
pubmed: 33140925
Can J Gastroenterol. 2007 Dec;21(12):839-42
pubmed: 18080057
Minerva Gastroenterol (Torino). 2021 Dec;67(4):339-347
pubmed: 33871224
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Med Ultrason. 2014 Sep;16(3):236-45
pubmed: 25110765
Hepatol Int. 2018 Nov;12(6):567-576
pubmed: 30284684
Crit Rev Oncog. 2020;25(1):57-70
pubmed: 32865911
Gastroenterology. 2008 Apr;134(4):960-74
pubmed: 18395077
Int J Mol Sci. 2021 Apr 26;22(9):
pubmed: 33925827
Clin Nutr. 2013 Jun;32(3):444-51
pubmed: 23068014
Obes Surg. 2008 Apr;18(4):371-7
pubmed: 18286348
Risk Manag Healthc Policy. 2021 Feb 09;14:491-501
pubmed: 33603515
Fundam Clin Pharmacol. 2018 Apr;32(2):209-215
pubmed: 29239015
Lipids Health Dis. 2021 Feb 26;20(1):22
pubmed: 33637088
Intern Emerg Med. 2019 Jan;14(1):51-57
pubmed: 30191534
J Appl Lab Med. 2022 Jan 5;7(1):259-267
pubmed: 34996079
Aliment Pharmacol Ther. 2015 Sep;42(6):731-40
pubmed: 26202818
Front Immunol. 2021 Mar 25;12:636803
pubmed: 33841420
Rev Recent Clin Trials. 2014;9(3):141-7
pubmed: 25514911
Indian J Gastroenterol. 2020 Feb;39(1):9-21
pubmed: 32291578
Lancet. 2014 May 17;383(9930):1749-61
pubmed: 24480518
Clin Mol Hepatol. 2019 Jun;25(2):160-167
pubmed: 30773001
Pharmacol Res. 2021 May;167:105484
pubmed: 33771699
Semin Liver Dis. 2017 Nov;37(4):388-400
pubmed: 29272899
PLoS Comput Biol. 2020 Sep 22;16(9):e1008244
pubmed: 32960884
Insights Imaging. 2014 Aug;5(4):441-55
pubmed: 24859758
Eur Rev Med Pharmacol Sci. 2013;17 Suppl 2:30-5
pubmed: 24443065
Clin Exp Hepatol. 2019 Mar;5(1):1-10
pubmed: 30915401
Nutrients. 2020 Mar 05;12(3):
pubmed: 32151020
Expert Opin Pharmacother. 2021 Sep;22(13):1729-1741
pubmed: 33896315
Dig Dis Sci. 2011 May;56(5):1524-34
pubmed: 21046243
Hepatoma Res. 2020;6:
pubmed: 32582865
Arq Gastroenterol. 2020 Oct-Dec;57(4):381-398
pubmed: 33331485
Nutrients. 2020 Sep 10;12(9):
pubmed: 32927776
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):813-819
pubmed: 28621554
J Inflamm (Lond). 2010 Mar 30;7:15
pubmed: 20353583
Clin Gastroenterol Hepatol. 2009 Feb;7(2):135-40
pubmed: 19118644
Transl Gastroenterol Hepatol. 2021 Jan 05;6:3
pubmed: 33409398
J Int Med Res. 2020 Dec;48(12):300060520978122
pubmed: 33327816
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Hepatobiliary Surg Nutr. 2021 Jan;10(1):100-102
pubmed: 33575294